Ketosteril to help prevent muscle and nutrition loss in nephrotic syndrome
Tests Ketosteril for preventing protein-energy wasting in adults with nephrotic syndrome.
Key facts
- Who runs it
- Military Institute od Medicine National Research Institute
- Where
- Poland8 sites in 1 countryChoose a country to see its sites
- Registry title
- Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 150 people, planned
- Started
- 3 Jan 2023
- Expected to end
- 31 Aug 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ketosteril
- Medium Protein Diet (MPD)
- Record updated
- 8 February 2023
Who can take part
The trial is looking for adults with nephrotic syndrome, newly found or come back, to test Ketosteril with a medium protein diet against the diet alone. The aim is to prevent loss of muscle and body stores.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- Nephrotic syndrome, new diagnosis or relapse. Kidney filtration (GFR) must be 30 mL/min/1.73m2 or higher. A relapse means proteinuria under 2.0 g/day or uPCR under 2000 mg/g in the 6 months before.
- Earlier treatment
- For a relapse: prednison dose of 10 mg/day or less in the last 3 months before it. No Ketosteril in the last 1 year.
- Biomarker or test result
- Serum albumin below 3.0 g/dL and protein in the urine over 3.5 g/day or over 50 mg/kg.
- Main reasons for not taking part
- Kidney disease from diabetes, HbA1c >7% (53 mmol/mol), lupus or small vessel vasculitis
- Positive ANA, anti-dsDNA or ANCA, HIV, hepatitis C or HBsAg tests
- Pregnancy, cancer or monoclonal gammopathy
- Body mass index of 40 kg/m2 or more
- Other clinical trial or Ketosteril use in the last 1 year
Show the full registry criteria (19)Hide the full registry criteria
Who can take part
- Nephrotic syndrome with serum albumin < 3.0 g/dL and daily proteinuria of > 3.5 g/day or > 50 mg/kg
- New diagnosis or relapse of nephrotic syndrome (defined as: proteinuria of < 2.0 g/day or uPCR < 2000 mg/g in the last 6 months prior to relapse and prednison dose equal to or less than 10 mg/day in the last 3 months prior relapse)
- Glomerular filtration rate qual to or higher than 30 mL/min/1.73m2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
Who cannot take part
- Positive antinuclear antibodies, anti-dsDNA or antineutrophil cytoplasmic antibodies (ANCA)
- Alcohol or drug abuse
- Participation in other clinical trial or the use of Ketosteril in the last 1 year prior to screening
- Diabetic kidney disease
- Positive anti-HIV or anti-hepatitis C antibodies, HBsAg
- Severe acute or chronic disease affecting nutritional status
- Mental disorders
- Failure to comply with medical recommendations, lack of cooperation
- HbA1c >7%
- Small vessels vasculitis
- Systemic lupus erythematosus
- Monoclonal gammopathy
- Pregnancy
- Body mass index >= 40 kg/m2
- Neoplasm
- Contraindication to Ketosteril
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Nephrotic syndrome
This trial is currently available in Poland.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this non-commercial clinical trial is to assess efficacy and safety of ketoanalogues of essential amino acids in the prevention of protein-energy wasting in nephrotic syndrome.
The 2 groups in the trial
- KA+MPDTreatment being tested
Ketosteril + Medium Protein Diet (MPD) for 12 months
Treatment: Ketosteril and Medium Protein Diet (MPD)
- MPDExisting treatment, for comparison
Medium Protein Diet (MPD) for 12 months
Treatment: Medium Protein Diet (MPD)
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- FORMA - a Multicenter Randomized-controlled Trial to Evaluate the Efficacy and Safety of Ketoanalogues of Essential Amino Acids in Prophylaxis of Protein-energy Wasting in Nephrotic Syndrome
- Plain-language title
- Ketosteril to help prevent muscle and nutrition loss in nephrotic syndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT05716880, who can take part
- Record updated
- 8 February 2023